Coronary Stents Market Size By Product (Bare Metal Stents, Drug Eluting Stents, Bioresorbable Vascular Scaffold), By End-use (Hospitals, Cardiac Centers, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

Published Date: Feb 2021  |  Report ID: GMI2966  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 110   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry trends

Coronary Stents Market size surpassed USD 6.7 billion in 2020 and is estimated to grow at 3.9% between 2021 and 2027. Frequent upgradation of technology will allow introduction of minimally invasive coronary stents, high accuracy level and more reliability. This can potentially increase the adoption rate and boost the market growth. Also, significant rise in number of people suffering from coronary heart diseases will lead to high demand for percutaneous coronary intervention procedures, thereby augmenting the market expansion. Various industry players are focusing on development of minimally invasive coronary stents to meet the growing patient needs and thus, fostering the market value.
 

Coronary Stents Market Research Report

Get more details on this report - Request Free Sample PDF
 

Coronary stents are essential medical devices that are used in critical life-saving procedures. Thus, it can be expected that the COVID-19 crisis won’t directly impact the manufacturing of such devices. However, the market can expect logistical disruptions especially due to the reliance on Chinese manufacturing. This could disrupt the supply of coronary stents and cause temporary shortages, thereby potentially increasing the prices of coronary stents and hindering the market revenue.
 

Increasing demand for percutaneous coronary intervention will spur the market demand

Growing number of coronary artery disease across the globe will positively impact the coronary stents market size in the coming years. Rising number of patient pool with chronic disease will drive the demand for percutaneous coronary intervention. According to the American Heart Association (AHA) on heart disease and stroke statistics report, approximately 116.3 million people suffered from cardiovascular diseases in U.S in 2019. Among those population, nearly 43.5% population were suffering from coronary heart disease. Thus, as number of people suffering from coronary artery disease is rising steadily, the demand for percutaneous coronary intervention will increase. This will lead to increase in acceptance rate of coronary stents, thereby propelling industry growth during the forecast timeframe.
 

Product recall and failure may slow down the industry expansion

Product failure and recall is one of the major reasons responsible for hindering the market growth. Coronary stents undergo stent deformation and plaque prolapse. Such product failures lead to serious patient outcomes, thereby leading to withdrawal of product from the market. For instance, Abbott initiated Class I recall for its Absorb Bioresorbable Vascular Scaffold (BVS) system form Australia. The reason for product recall was high rates of adverse events such as myocardial infraction and scaffold thrombosis from use of the product. Therefore, product recall and failure of coronary stents ultimately escalated the overall healthcare expenditure, thereby impacting the industry value.
 

Various advantages and application associated with drug eluting stents (DES) will fuel the market progression

Coronary Stents Market Share

Get more details on this report - Request Free Sample PDF
 

The drug eluting stents (DES) segment dominated more than 85.4% of the coronary stents market share in 2020 led by the advantages associated with drug eluting stents such as lower re-obstruction rate and superior treatment outcome, among others. Furthermore, DES are used in wide array of application such as percutaneous coronary intervention and myocardial infraction. Also, various market leaders are investing in R&D activities to develop technologically advanced drug eluting stents. Thus, the usage of DES in various application and technological advancements will impel the industry revenue.
 

Rising usage of coronary stents in hospital settings for various treatments will enhance the segment growth

Hospital end-use segment in the coronary stents market was valued at USD 2.9 billion in 2020. Hospitals are well equipped with medical devices including coronary stents, as they are essential devices and widely used in various minimally invasive surgical procedures. Thus, increased implementation and adoption of coronary stents in hospital setting will drive the segment revenue. Additionally, changing lifestyle, acceptance of unhealthy habits such as alcohol and smoking along with environmental factors including pollution increases the burden of cardiovascular diseases. Therefore, significant increase in hospital admissions will stimulate the demand for advanced treatment solutions, offering immense growth opportunities for the market during the forecast timeline.
 

Various industry participants are launching novel products in U.S. and Canada

North America Coronary Stents Market

Get more details on this report - Request Free Sample PDF
 

North America coronary stents market held over 28.8% of the revenue share in 2020. Major companies are focusing to launch next generation coronary stents to meet the growing demand for patient population. For instance, in April 2019, Biotronik announced the U.S. commercial launch of its PK Papyrus covered coronary stent system. The device is used in the emergency treatment of acute coronary perforation. However, the North America market is projected to witness a dip during the forecast timeframe. This is owing to decrease in number of PCI and myocardial infarction (angioplasty) procedures in U.S.
 

Adoption of inorganic business strategies will pave growth opportunities for companies operating in the market

Prominent companies operating in the market include Abbott, B Braun, Biosensors, Biotronik, Boston Scientific, Medtronic and Terumo Corporation. New product launch & approval, acquisition and collaboration are the most commonly adopted business strategies to sustain market position.
 

Some of the recent industry developments:

  • In February 2019, Biotronik received approval from U.S. FDA for its Orsiro drug eluting stent that is an ultrathin bioresorbable stent. The product is intended for percutaneous coronary intervention (PCI) procedures. This new product launch strategy enabled company to strengthen its product portfolio and expand the existing customer base in the market.
  • In May 2018, Abbott announced launch of a new generation Xience Sierra drug-eluting stent after approval from U.S. FDA. This new product launch enabled the company to expand its product portfolio in the treatment of coronary artery disease (CAD) and strengthen its market presence.
     

The coronary stents market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Product

  • Bare metal stents
  • Drug eluting stents
  • Bioresorbable vascular scaffold

Market, By End-use

  • Hospitals
  • Cardiac centers
  • Ambulatory surgical centers
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
       

Frequently Asked Questions (FAQ) :

The market for coronary stents exceeded USD 6.7 billion in 2020 and will expand at a moderate CAGR of 3.9% over the forecast period 2021-2027.
The market share from the drug eluting stents (DES) segment was pegged at over 85.4% in 2020 and will thrive due to lower re-obstruction rate and superior treatment outcomes.
The market value from the hospital segment stood at USD 2.9 billion in 2020 and will expand with the growth of minimally invasive surgical procedures.
North America coronary stents market revenue held more than 28.8% of the global share in 2020 and will expand with the launch of next-gen products.
Key producers worldwide include Medtronic, Boston Scientific, B Braun, Abbott, Biosensors and Terumo Corporation, among others.

Premium Report Details

  • Published Date: Feb 2021
  • Pages: 110
  • Tables: 114
  • Charts / Figures: 16
  • Companies covered: 10
  • Countries covered: 15

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X